In eosinophilic individuals , benralizumab reduced exacerbation rates compared with placebo in the @ mg group ( @ vs @ , reduction @ % , @ % CI @ to @ , p = @ ) but not in the @ mg group ( @ vs @ , difference -@ % , @ % CI -@ to @ , p = @ ) or the @ mg group ( @ vs @ , reduction @ % , @ % CI @ to @ , p = @ ) .